Nalmefene hydrochloride

Description

Nalmefene hydrochloride has been introduced in the U.S.A. for opioid reversal following surgery, and in the reversal of opioid overdoses and epidurally administered narcotics. Nalmefene is an opioid antagonist that inhibits respiratory, analgesic and subjective effects of opioids. It has a higher potency, a longer duration of action, and superior bioavailability than the structurally related naltrexone. Nalmefene has a wide spectrum of biological activity and is in clinical trials for the treatment of interstitial cystitis, recalcitrant pruritus of cholestasis, stroke, rheumatoid arthritis, shock, CNS trauma, and alcoholism. Studies indicate that nalmefene does not induce morphine-like effects and has no apparent abuse potential.

Originator

IVAX (U.S.A.)

The Uses of Nalmefene hydrochloride

Nalmefene Hydrochloride is a structural analog of Naltrexone (N285780) with opiate antagonist activity used in pharmaceutical treatment of alcoholism. Other pharmacological applications of this compound aim to reduce food cravings, drug abuse and pulmonary disease in affected individuals. Used as an opioid-induced tranquilizer on large animals in the veterinary industry. Narcotic antagonist

What are the applications of Application

Nalmefene hydrochloride is an opioid receptor antagonist

brand name

Revex

Storage

Desiccate at RT

References

1) Osborn et al. (2010), In vivo characterization of the opioid antagonist nalmefene in mice; Life Sci., 86 624 2) Butelman et al. (2009), Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in non-human primates: fast onset and entry in cerebrospinal fluid; J. Pharmacol. Exp. Ther., 328 588 3) Butelman et al. (2008), The effects of herkinorin, the first mu-selective ligand from salvinorin A-derived scaffold, in neuroendocrine biomarker assay in nonhuman primates; J. Pharmacol. Exp. Ther., 327 154 4) Soyka and Rosner (2008), Opioid antagonists for pharmacological treatment of alcohol dependence – a critical review; Curr. Drug Abuse Rev., 1 280